Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes

被引:54
作者
Roychowdhury, S
Vyas, PM
Reilly, TP
Gaspari, AA
Svensson, CK
机构
[1] Univ Iowa, Coll Pharm, Div Pharmaceut, Iowa City, IA 52242 USA
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Immunotoxicol Drug Safety Evaluat, Syracuse, NY USA
[3] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA
关键词
D O I
10.1124/jpet.105.086009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sulfonamide- and sulfone- induced hypersensitivity reactions are thought to be mediated through bioactivation of parent drug molecule( s) to their respective reactive metabolite( s). Recent studies have demonstrated that keratinocytes can bioactivate sulfonamides and sulfones. Using enzyme- linked immunosorbent assay and hapten- specific rabbit antisera developed in our laboratory, we found that incubation of either normal human epidermal keratinocytes ( NHEKs) or an immortalized human keratinocyte cell line ( HaCaT) with sulfamethoxazole ( SMX) or dapsone ( DDS) resulted in the formation of drug/ metabolite protein adducts. The formation of these adducts with SMX was increased in the presence of ascorbic acid, whereas N- acetylcysteine decreased adduct formation with both SMX and DDS. Adduct formation was confirmed using confocal microscopy when NHEKs were incubated with SMX, DDS, or their respective arylhydroxylamine metabolites. Cellular distribution of adducts was compared in permeable versus nonpermeable NHEKs. Exposure to SMX, DDS, or dapsone hydroxylamine resulted in the formation of intracellular adducts, whereas SMX hydroxylamine also resulted in the presence of adducts on the cell surface. In summary, our work shows that keratinocytes can bioactivate SMX/ DDS to form drug- protein adducts, which may be acquired by antigen- presenting cells upon keratinocyte cell death, evoking an immune response. In addition, keratinocytes may themselves present antigen to hapten- specific cytotoxic T lymphocytes. Furthermore, our results also suggest that different sulfonamides/ sulfones may have different protein targets for in situ haptenation in keratinocytes.
引用
收藏
页码:43 / 52
页数:10
相关论文
共 40 条
[11]  
MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462
[12]   ORAL-THERAPY FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE VERSUS TRIMETHOPRIM DAPSONE [J].
MEDINA, I ;
MILLS, J ;
LEOUNG, G ;
HOPEWELL, PC ;
LEE, B ;
MODIN, G ;
BENOWITZ, N ;
WOFSY, CB .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (12) :776-782
[13]  
Naisbitt DJ, 2001, CURR OPIN ALLERGY CL, V1, P317
[14]   Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity [J].
Naisbitt, DJ ;
Hough, SJ ;
Gill, HJ ;
Pirmohamed, M ;
Kitteringham, NR ;
Park, BK .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (06) :1393-1407
[15]   Immunopharmacology of hypersensitivity reactions to drugs [J].
Naisbitt, DJ ;
Pirmohamed, M ;
Park, BK .
CURRENT ALLERGY AND ASTHMA REPORTS, 2003, 3 (01) :22-29
[16]   Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation [J].
Naisbitt, DJ ;
Farrell, J ;
Gordon, SF ;
Maggs, JL ;
Burkhart, C ;
Pichler, WJ ;
Pirmohamed, M ;
Park, BK .
MOLECULAR PHARMACOLOGY, 2002, 62 (03) :628-637
[17]   Antigenicity and immunogenicity of sulphamethoxazole:: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo [J].
Naisbitt, DJ ;
Gordon, SF ;
Pirmohamed, M ;
Burkhart, C ;
Cribb, AE ;
Pichler, WJ ;
Park, BK .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (02) :295-305
[18]  
NAKAMURA H, 1995, J PHARMACOL EXP THER, V274, P1099
[19]   Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective [J].
Park, BE ;
Pirmohamed, M ;
Kitteringham, NR .
CHEMICAL RESEARCH IN TOXICOLOGY, 1998, 11 (09) :969-988
[20]   DRUG-PROTEIN CONJUGATION AND ITS IMMUNOLOGICAL CONSEQUENCES [J].
PARK, BK ;
KITTERINGHAM, NR .
DRUG METABOLISM REVIEWS, 1990, 22 (01) :87-144